The Lancet Oncology· Andrew Oar, Andrew Kneebone, Katrin M Sjoquist, David Espinoza, Mark Lee, Hien Le, Leily Gholamrezaei, Julie Chu, James Lynam, Girish Mallesara, Dominique Lee, Dinesh Vignarajah, Iain Ward, Jaswinder Samra, Andrew Barbour, Angela Whitehead, Susan Brooks, Anna Nicholson, Tim Wei Wang, Weng Ng, Fathalla Ali, Derrick Siu, Juanita Lopez Gaitan, Olivia Cook, Alisha Moore, Martinus B Oostendorp, Sonia Yip, John Shakeshaft, David Pryor, Nam Nguyen, David Goldstein, Australasian Gastro-Intestinal Trials Group (AGITG)·· 4 小时前AI 评分45
高危局限性胰腺癌围手术期化疗联合立体定向放疗对比单纯围手术期化疗（MASTERPLAN）：澳大利亚和新西兰胃肠道临床试验组开展的开放标签、多中心、随机II期临床试验
[Articles] Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials Group
AI 导读
MASTERPLAN临床试验显示，高危局限性胰腺导管腺癌患者在化疗基础上加用立体定向放疗，与局部区域复发显著减少相关，且毒性未显著增加。该研究为开放标签、多中心、随机II期临床试验，结果仍需更大规模研究进一步验证。
来源：The Lancet Oncology · thelancet.com